US006376519B1

(12) **United States Patent**
Reddy et al.

(10) **Patent No.: US 6,376,519 B1**
(45) **Date of Patent: Apr. 23, 2002**

(54) **1-(4-SULFAMYLARYL)-3-SUBSTITUTED-5-ARYL-2-PYRAZOLINES AND INHIBITORS OF CYCLOOXYGENASE-2**

(75) Inventors: **E. Premkumar Reddy**, Villanova; **M. V. Ramana Reddy**, Upper Darby, both of PA (US)

(73) Assignee: **Temple University-of the Commonwealth of Higher Education**, Philadelphia, PA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/595,760**

(22) Filed: **Jun. 16, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/139,416, filed on Jun. 16, 1999.

(51) **Int. Cl.**[7] **C07D 231/06**; C07D 401/04; C07D 405/04; A61K 31/402; A61K 31/4439

(52) **U.S. Cl.** **514/341**; 514/403; 546/275.4; 548/364.4; 548/364.7; 548/365.7; 548/379.1; 548/379.7

(58) **Field of Search** 548/365.7, 379.1, 548/379.7, 364.4, 364.7; 546/275.4; 514/341, 403

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,640,056	A	5/1953	Kendall et al.	548/379.7
2,740,793	A	4/1956	Kendall et al.	548/379.7
3,836,523	A	9/1974	Turner	540/534
3,865,816	A	2/1975	Mengler	548/379.7
3,980,795	A	9/1976	Gante et al.	424/273
4,045,571	A	8/1977	Möller et al.	424/273
4,407,803	A	10/1983	Haviv et al.	424/258
4,447,442	A	5/1984	Dusza et al.	424/273
4,448,973	A	5/1984	Dusza et al.	548/362
4,968,687	A	11/1990	Findeisen et al.	514/269
5,134,148	A	7/1992	Crawley et al.	514/312
5,300,522	A	4/1994	Klaus et al.	514/450
5,334,719	A	8/1994	Frenette	546/174
5,403,838	A	4/1995	Kirstgen et al.	514/224.2
5,434,178	A	7/1995	Talley et al.	514/406
5,700,816	A	12/1997	Isakson et al.	514/326
5,756,529	A	5/1998	Isakson et al.	514/406
5,908,852	A	6/1999	Talley et al.	514/340
5,972,986	A	10/1999	Seibert et al.	514/406
6,025,353	A	2/2000	Masferrer et al.	514/210

FOREIGN PATENT DOCUMENTS

WO	WO 99/32884	12/1999

OTHER PUBLICATIONS

Database CAS online on STN (Columbus, Ohio) AN 199:78401, doc No. 132:12302, Cuberes–Altisent et al., 'Diarylpyroles as Inhibitors of Cyclooxygenase–2', WO 99/62884, Dec. 9, 1999.

H.M. Faidallah, et al., Trisubstituted Pyrazoles Of Possible Hypoglycemic Activity, Jan.–Feb. 1992, pp. 8–13, Pak. J. Sci. Ind. Res., vol. 35, Nos. 1–2.

Database CAS online on STN (Columbus, Ohio) AN 1992:591744, doc. No. 117:191744, Faidallah et al., Pak. J. Sci. Ind. Res. (1992) 35(1–2), 8–13.

Makki et al., Chemical Abstracts, 121:134017, 1994.*

* cited by examiner

Primary Examiner—Fiona T. Powers
(74) *Attorney, Agent, or Firm*—Drinker Biddle & Reath LLP

(57) **ABSTRACT**

Compounds of the formula

(I)



wherein:

X is selected from the group consisting of trihalomethyl, C_1–C_6 alkyl, and a group of formula II:

(II)



wherein:

R_3 and R_4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C_1–C_6 alkyl;

C_1–C_6 alkoxy; carboxy; C_1–C_6 trihaloalkyl; and cyano;

Z is selected from the group consisting of substituted and unsubstituted aryl; or a pharmaceutically acceptable salt thereof. The compounds are inhibitors of cyclooxygenase-2 activity. They are useful for treating cyclooxygenase-mediated disorders, including, for example, inflamation, neoplastic disorders and angiogenesis-mediated disorders.

47 Claims, 1 Drawing Sheet